Organization
Sandoz, Inc.
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Sandoz, Inc.
... until April 1, 2032. These same patents are similarly being asserted against Sandoz Inc. and Lupin Ltd. in Hatch-Waxman litigation planned for trial in mid-2019 ...
... Neulasta [1]. The Phase I study, conducted in healthy volunteers, confirmed that Sandoz biosimilar pegfilgrastim matches the reference biologic in terms of PK, PD, safety ...
... study demonstrates matching pharmacokinetic (PK), pharmacodynamic (PD), safety and immunogenicity profiles of Sandoz biosimilar pegfilgrastim and reference medicine * Pegfilgrastim is a long-acting version of ...
... preliminary talks with generic drug manufacturers such as Mylan myl and Novartis’s Sandoz. The report gave Mylan’s stock price a 4.5% pop in after-hours trading. ...
... YASTEST * Sandoz strengthens position as global leader in biosimilars with new immunology data from ...
... clarified and addressed, the drugmaker added. Hikma’s lengthy delay could make Novartis’ Sandoz a come-from-behind winner in the race to bring a cheap copy of ...
... EQUIRA study1. The Phase III comparative safety and efficacy study shows that Sandoz biosimilar Erelzi(etanercept-szzs) matches the reference medicine Enbrel, in terms of efficacy and ...
... brands from Eli Lilly, Ipsen, Ferring, Merck Group, Novo Nordisk, Pfizer, and Sandoz, this report reveals: What doctors really want from medical affairs teams. Which ...
... and some manufacturing facilities, the news service said, citing anonymous sources. Novartis' Sandoz unit became the largest seller of generic dermatology meds with its 2012 ...
... is a long-acting formulation of filgrastim (granulocyte colony-stimulating factor, or G-CSF) and Sandoz is seeking approval for use of its biosimilar in the same indication ...
... to 18 companies and 15 medicines on Tuesday, including Novartis' generic unit Sandoz and India-based Sun Pharmaceutical Industries, people familiar with the matter said. The ...
... YASTEST * Comprehensive data package demonstrates that Sandoz biosimilar pegfilgrastim matches the reference biologic in terms of safety, efficacy and ...
... from the gross profit on authorized generic sales of Angiomax® (bivalirudin) by Sandoz, Inc. and worldwide Angiomax®/Angiox® (bivalirudin) net product sales. Other products recorded aggregate ...
... with strong growth in Surgical and continued growth in Vision Care * Sandoz grew 1% (cc) driven by growth outside the US, fully offsetting US ...
... the US, Western Europe and Israel: · Hospira (Pfizer) · Mylan · Sandoz (Novartis) · STADA Arzneimittel · Teva Pharmaceutical Industries Chapter 5 profiles leading ...
... 20mg and 40mg) injections, pricing pressure will increase on Teva's Copaxone and Sandoz's Glatopa, the first-to-market generic, and payer pressure can be expected to markedly ...
... Novartis International AG / Sandoz proposed biosimilar adalimumab matches reference biologic in terms of efficacy and safety ...
... Sandoz, a Novartis Division, and the pioneer and global leader in biosimilars, announced ...
Want to see the full history on Sandoz, Inc.? Upgrade to RelSci Pro now!
Start My Free Trial